Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Publication number: 20110091466Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).Type: ApplicationFiled: October 7, 2010Publication date: April 21, 2011Inventors: MANUEL L. PENICHET, BIRGIT C. SCHULTES, CHRISTOPHER F. NICODEMUS, TRACY R. DANIELS, GUSTAVO HELGUERA, JOSE A. RODRIGUEZ
-
Patent number: 7919087Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.Type: GrantFiled: May 29, 2007Date of Patent: April 5, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7910100Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding these anti-EAG1 antibodies, antibody fragments or derivatives and to vectors comprising such nucleic acid molecules. The invention additionally relates to methods for the preparation of such anti-EAG1 antibodies, antibody fragments or derivatives thereof, pharmaceutical compositions comprising these antibodies, antibody fragments or derivatives, and methods of using the antibodies, antibody fragments or derivatives or the compositions for a variety of purposes, such as diagnosing disease, treating disease, assessing for the presence of EAG1-expressing cells, or blocking EAG1 function in cells.Type: GrantFiled: October 4, 2005Date of Patent: March 22, 2011Assignee: Max-Planck-Gesellschaft zur Forderung der WissenInventors: Walter Stühmer, Hendrik Knötgen, David Gómez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne
-
Patent number: 7910103Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: October 1, 2001Date of Patent: March 22, 2011Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7892550Abstract: The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.Type: GrantFiled: October 2, 2006Date of Patent: February 22, 2011Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
-
Patent number: 7892549Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.Type: GrantFiled: February 3, 2003Date of Patent: February 22, 2011Assignee: Genentech, Inc.Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
-
Patent number: 7887808Abstract: Naturally-occurring variants of human Rgr oncogene protein, in particular, abnormally truncated variants found in T cell malignancies, as well as the human Rgr protein are encompassed by the present invention. Also included are antibodies thereto and nucleic acid molecules encoding human Rgr protein and naturally-occurring variants thereof. The present invention further provides methods for diagnosing and treating T cell malignancies associated with abnormally truncated transcripts of human rgr oncogene and/or abnormal truncation of human Rgr protein.Type: GrantFiled: April 25, 2008Date of Patent: February 15, 2011Assignee: New York UniversityInventors: Angel Pellicer, Peter Leonardi, Giorgio Inghirami
-
Patent number: 7883702Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: GrantFiled: August 25, 2005Date of Patent: February 8, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Publication number: 20110027190Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.Type: ApplicationFiled: June 4, 2008Publication date: February 3, 2011Inventors: Max Hasmann, Helmut Lenz, Werner Scheuer
-
Patent number: 7879327Abstract: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: June 11, 2007Date of Patent: February 1, 2011Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshihiro Noguchi, Akemi Baba, Mitsuharu Hanada
-
Patent number: 7862817Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: GrantFiled: January 27, 2005Date of Patent: January 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7862994Abstract: This invention provides agents determined to be capable of inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+cell and agents determined to be capable of inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+cell. This invention also provides methods to identify such agents. This invention further provides methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+cell susceptible to infection by a T cell-tropic isolate of HIV-1.Type: GrantFiled: July 12, 2001Date of Patent: January 4, 2011Assignee: Progenics Pharmaceuticals Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
-
Publication number: 20100330082Abstract: NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.Type: ApplicationFiled: October 1, 2008Publication date: December 30, 2010Applicant: GENENTECH INC.Inventors: Meredith Hazen, Jo-Anne S. Hongo, Victoria Smith, Susanna Stinson
-
Patent number: 7850966Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.Type: GrantFiled: September 24, 2008Date of Patent: December 14, 2010Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Patent number: 7846441Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.Type: GrantFiled: December 10, 1998Date of Patent: December 7, 2010Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Patent number: 7837995Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: December 9, 2002Date of Patent: November 23, 2010Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7834155Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: GrantFiled: August 29, 2005Date of Patent: November 16, 2010Assignee: Immunogen Inc.Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
-
Patent number: 7833528Abstract: Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.Type: GrantFiled: October 27, 2006Date of Patent: November 16, 2010Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Serengulam V. Govindan, Hans J. Hansen
-
Patent number: 7824680Abstract: The invention provides methods for detecting and inhibiting angiogenesis, endothelial cell adhesion, and endothelial cell migration using agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention further provides methods for screening test compounds for their ability to inhibit angiogenesis, endothelial cell adhesion, or endothelial cell migration by employing agents which inhibit the specific binding of integrin ?4?1 to one or more of its ligands. The invention additionally relates to methods for isolating endothelial progenitor cells which express integrin ?4?1. The methods of the invention are useful in, for example, diagnosing and inhibiting pathological conditions that are associated with angiogenesis, endothelial cell adhesion, and/or endothelial cell migration.Type: GrantFiled: August 1, 2002Date of Patent: November 2, 2010Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Patent number: 7820166Abstract: The present invention relates to a polypeptide construct comprising at least one CDR3 region, wherein at least one of the at least CDR3 regions comprises at least one substitution in the amino acid sequence YYDDHY (SEQ ID NO.1) and wherein the at least one substitution comprises: in the first position of SEQ ID NO.1 a substitution from Y to H; in the second position of SEQ ID NO. 1 a substitution from Y to S, from Y to N, from Y to F or from Y to H; in third position of SEQ ID NO. 1 a substitution from D to N or from D to E; in the forth position of SEQ ID NO. 1 a substitution from D to Q, from D to A, from D to V, from D to E or from D to G; in the fifth position of SEQ ID NO. 1 a substitution from H to Q, from H to P, from H to Y, from H to R or from H to N; or in the sixth position a substitution from Y to N.Type: GrantFiled: October 10, 2003Date of Patent: October 26, 2010Assignee: Micromet AGInventor: Antonio Lanzavecchia
-
Patent number: 7820164Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: January 12, 2010Date of Patent: October 26, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Publication number: 20100260769Abstract: The invention relates to novel binding molecules that specifically bind endosialin (TEM-1) including antibodies, such as monoclonal antibodies, or antigen-binding portions of antibodies, and methods and compositions comprising such binding molecules.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: MORPHOTEK, INC.Inventors: Philip M. Sass, Brad Kline, Nicholas Nicolaides, Luigi Grasso, Stephen Harley
-
Patent number: 7776330Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: GrantFiled: September 25, 2007Date of Patent: August 17, 2010Assignee: City of HopeInventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
-
Patent number: 7744871Abstract: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.Type: GrantFiled: April 20, 2006Date of Patent: June 29, 2010Assignee: Centro De Inmunologia MolecularInventors: Rolando Pérex Rodriguez, Gisela Maria González Marinello, Tania Crobet Ramos, Irene Beausoleil Del Gado
-
Patent number: 7744877Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.Type: GrantFiled: September 11, 2002Date of Patent: June 29, 2010Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 7744863Abstract: A method of inhibiting Th1 immune response in a subject in need of such treatment which comprises administering to the subject effective amounts for inhibiting Th1 immune response of an anti-CD3 monoclonal antibody and IL-5 or an analogue or mimetic thereof.Type: GrantFiled: November 24, 2000Date of Patent: June 29, 2010Inventors: Bruce Milne Hall, Suzanne Jean Hodgkinson
-
Patent number: 7740847Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.Type: GrantFiled: July 18, 2005Date of Patent: June 22, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins
-
Patent number: 7736652Abstract: The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.Type: GrantFiled: April 5, 2002Date of Patent: June 15, 2010Assignee: The Regents of the University of CaliforniaInventors: Manuel L. Penichet, Jay Dela Cruz, Lisan Peng, Sherie L. Morrison
-
Publication number: 20100143356Abstract: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.Type: ApplicationFiled: February 17, 2010Publication date: June 10, 2010Applicant: MULTIMMUNE GMBHInventor: Gabriele Multhoff
-
Publication number: 20100143244Abstract: A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.Type: ApplicationFiled: December 4, 2008Publication date: June 10, 2010Inventor: Nathaniel C. Lallatin
-
Publication number: 20100143370Abstract: Kit of parts for treating a malignant pathology, an auto-immune disease or an infectious disease, comprising an effector cell which expresses the Fc?RIII receptor (CD16) on its surface, and a monoclonal antibody, the affinity of the Fc region of said monoclonal antibody for CD16 being greater than the affinity of the Fc region of the polyclonal immunoglobulins for CD16.Type: ApplicationFiled: April 25, 2008Publication date: June 10, 2010Applicant: LFB BIOTECHNOLOGIESInventors: Christophe De Romeuf, Nathalie Fournier, Nadine Fernandez
-
Patent number: 7732578Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: GrantFiled: February 8, 2005Date of Patent: June 8, 2010Assignee: Arrowsmith Technology Licensing LLCInventor: Jefferson Foote
-
Patent number: 7713526Abstract: The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.Type: GrantFiled: November 1, 2002Date of Patent: May 11, 2010Assignee: The Regents of the University of CaliforniaInventors: Chae-Seo Rhee, Malini Sen, Christina Wu, Lorenzo M. Leoni, Maripat Corr, Dennis A. Carson
-
Patent number: 7700085Abstract: The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject.Type: GrantFiled: May 20, 2004Date of Patent: April 20, 2010Assignee: The Trustees of Columbia University in the City of New YorkInventors: David M. Stern, Ann Marie Schmidt
-
Patent number: 7695716Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.Type: GrantFiled: April 11, 2008Date of Patent: April 13, 2010Assignee: Seattle Genetics, Inc.Inventors: Jonathan G. Drachman, May Kung Sutherland, Eric Sievers, Grant Risdon, Alan Wahl, Tim Lewis
-
Patent number: 7682612Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: November 9, 1999Date of Patent: March 23, 2010Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 7670804Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: October 30, 2007Date of Patent: March 2, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
Patent number: 7666414Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: September 2, 2005Date of Patent: February 23, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Neil Bander -
Patent number: 7666415Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.Type: GrantFiled: June 9, 2009Date of Patent: February 23, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7662384Abstract: The present invention provides methods for direct killing of cancer cells using anti-?5?1 antibodies. Generally, the method comprises contacting a cancer cell that expresses ?5?1 on its surface with an anti-?5?1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-?5?1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.Type: GrantFiled: March 24, 2005Date of Patent: February 16, 2010Assignee: Facet Biotech CorporationInventors: Vanitha Ramakrishnan, Vinay Bhaskar, Sun Ho, Richard Murray, Debbie Law
-
Patent number: 7648703Abstract: A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M.Type: GrantFiled: January 13, 2005Date of Patent: January 19, 2010Assignee: GlaxoSmithKline LLCInventors: Vincent C. Knick, Julie Beth Stimmel, Linda M. Thurmond
-
Patent number: 7641891Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: October 30, 2007Date of Patent: January 5, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7632925Abstract: The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.Type: GrantFiled: September 24, 2007Date of Patent: December 15, 2009Assignee: Micromet AGInventors: Peter Kufer, Tobias Raum
-
Publication number: 20090238755Abstract: Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: November 13, 2007Publication date: September 24, 2009Inventor: Neil H. Bander
-
Publication number: 20090226367Abstract: The present invention provides combination therapy methods, formulations and kits useful for managing or treating a CA 125-related disorder or symptom thereof. In one aspect, the present invention provides methods for managing or treating a cell proliferative disorder, such as a cancer, for example, ovarian cancer, comprising administering a combination of (a) a sensitizer, such as, for example, paclitaxel, and (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides, hi some embodiments of the methods provided, the antibody is conjugated to a cytotoxic agent such as a radiolabel. In another aspect, the present invention provides pharmaceutical compositions comprising (a) a sensitizer; (b) an antibody that preferentially binds cell-associated CA 125 polypeptides relative to shed CA 125 polypeptides; and, (c) a pharmaceutically acceptable excipient, diluent, or carrier.Type: ApplicationFiled: March 8, 2006Publication date: September 10, 2009Applicant: Euro-Celtique S.A.Inventor: Earl F. Albone
-
Publication number: 20090202561Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.Type: ApplicationFiled: March 27, 2009Publication date: August 13, 2009Inventors: Jennie P. MATHER, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
-
Patent number: 7569554Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.Type: GrantFiled: May 14, 2004Date of Patent: August 4, 2009Assignee: Idera Pharmaceuticals, Inc.Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshmi Bhagat, Dong Yu
-
Patent number: 7566452Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: May 4, 1999Date of Patent: July 28, 2009Assignee: New York UniversityInventors: Robert J. Schneider, Sumayah Jamal
-
Patent number: 7563439Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: October 24, 2007Date of Patent: July 21, 2009Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: RE40811Abstract: The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.Type: GrantFiled: November 15, 1993Date of Patent: June 30, 2009Assignee: Board of Regents of the University of WashingtonInventor: Thalia Papayannopoulou